Alvotech
ALVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. With a market capitalization of $1.63B, it sits in small-cap territory. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Market Cap
$1.63B
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
20.06
EPS (TTM)
$-0.62
EPS (Fwd)
$0.23
ROE
—
ROA
2.2%
Cash
$142.8M
Total Debt
$1.45B
Free CF
-$123.1M
52W Change
-45.5%
Annual Financials
Cash vs Debt
Where ALVO stands vs its 150-day and 200-day moving averages
As of the October 5, 2026 close, ALVO finished 37.97% above its 150-day moving average ($3.95) and 30.38% above its 200-day moving average ($4.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALVO overbought or oversold?
At the October 5, 2026 close, ALVO's RSI(14) was 58.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ALVO has $142.8M in cash with $1.45B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$123.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROA of 2.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $83.0M (2022) to $586.3M (2025), reflecting a 606% increase over the period.
ALVO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Alvotech carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALVO.